Drugs News and Research

RSS

Underwood-Memorial Hospital joins Jefferson Neuroscience Network as New Jersey participant

Underwood-Memorial Hospital of Woodbury, New Jersey has joined the Jefferson Neuroscience Network (JNN) as one of the first New Jersey participants. Through this collaboration, Jefferson and Underwood will provide some of the most sophisticated care and expertise available to patients with time-sensitive neurovascular diseases.

1 Dec 2010

Research shows anti-microbial medications lead to acute liver failure

New research shows that anti-microbial medications are a common cause of drug-induced liver injury (DILI) leading to acute liver failure (ALF), with women and minorities disproportionately affected.

1 Dec 2010

GenSpera expands G-202 Phase I safety trial to CTRC at University of Texas Health Science Center

GenSpera, Inc. announced its intention to expand its Phase I safety trial to study G-202 in relapsed, refractory cancer patients to the Cancer Therapy and Research Center (CTRC) at The University of Texas Health Science Center at San Antonio in San Antonio, TX. The expansion is dependent upon a successful review of the clinical protocol by the Health Science Center Institutional Review Board (IRB). The company anticipates admitting the first patient at this site in the first quarter of 2011.

1 Dec 2010

PhaseBio initiates Glymera Phase 1/2a clinical trial in patients with Type 2 diabetes

PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has begun Phase 1/2a clinical testing with its lead compound, Glymera(PB1023), in patients with Type 2 diabetes.

1 Dec 2010

NIA awards Aphios Phase I Fast Track SBIR grant for development of novel AD nanodrug

Aphios® Corporation today announced that it was awarded Phase I of a Fast Track SBIR grant from the National Institute of Aging (NIA), National Institutes of Health (NIH) for Developing a Novel Alzheimer's Disease Nanodrug.

30 Nov 2010

New findings offer insights into novel treatment avenue for Crohn's Disease, sarcoidosis

A new finding out in the December 1st issue of Genes & Development offers insight into a new treatment avenue for two painful inflammatory diseases: Crohn's Disease and sarcoidosis.

30 Nov 2010

Ikaria initiates enrollment in LUCASSIN Phase III trial for HRS Type 1

Ikaria, Inc. announced that it has enrolled the first patients in its pivotal Phase III trial for LUCASSIN® (terlipressin). The multi-center, randomized, placebo-controlled, double-blind trial is known as the REVERSE Trial.

30 Nov 2010

Opinions: Obama's Global Fund pledge; harm reduction in Iran; HIV prevention; African development

There are some encouraging signs in the epic battle against AIDS and HIV infections. But those bright spots dim considerably in the face of the fact that about 7,100 people a day become infected.

30 Nov 2010

Intellikine and MMRC commence INK128 Phase I trial in multiple myeloma

Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a phase I trial of INK128, a novel, orally-available small molecule kinase inhibitor of the TORC1 and TORC2 complexes, in patients with multiple myeloma.

30 Nov 2010

First Edition: November 30, 2010

Today's headlines include reports on congressional action on the Medicare doc 'pay fix' as well as results from a new poll related to how the public thinks Medicare should be addressed in the context of deficit reduction.

30 Nov 2010

Prescription rates for controlled medications double for teens, young adults

Adolescents and young adults are most likely to abuse prescription medications. Yet prescription rates for controlled medications, or drugs the Drug Enforcement Administration deems as having the potential for abuse, have nearly doubled for those age groups in the past 14 years, according to a recent study published in Pediatrics. Overall, a controlled medication was prescribed for young adults at approximately one out of every six visits and for young adult by adolescents one out of every nine encounters.

30 Nov 2010

First-ever selective irreversible inhibition of viral protease using targeted covalent drug

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the first-ever selective irreversible inhibition of a viral protease using a targeted covalent drug.

30 Nov 2010

Emergency artesunate suppositories are cost-effective intervention for children with suspected severe malaria

Giving emergency artesunate suppositories to children with suspected severe malaria before referring them for treatment is a cost-effective intervention that can substantially improve the management of childhood malaria in remote African settings, according to a new study led by Boston University School of Public Health [BUSPH] researcher Yesim Tozan, PhD.

30 Nov 2010

State legislatures ask: Are insurers practicing medicine without a license?

A survey by the Global Healthy Living Foundation, www.ghlf.org, a non-profit patient advocacy group, shows that up to 70 percent of prescription medications are changed by health insurers, denying patients the drugs their doctors prescribe.

30 Nov 2010

FG-2216 drug offers new treatment option for kidney disease-related anemia

A new drug called FG-2216 can stimulate production of the hormone erythropoietin (EPO) in dialysis patients—possibly offering a new approach to treatment of kidney disease-related anemia, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

30 Nov 2010

Resverlogix files new patent for dosing combinations of RVX-208, statin therapeutics

Resverlogix Corp. is pleased to announce today that it has filed additional new patent protection based on novel findings derived from its recently completed ASSERT Phase 2 clinical trial.

30 Nov 2010

International Harm Reduction Conference to focus on HIV/AIDS epidemic

Injecting drug use and growing HIV/AIDS epidemic in Middle East and North Africa region to be focus of the International Harm Reduction conference taking place in Beirut, Lebanon April 3-7 2011

30 Nov 2010

RCSI researchers discover potential new target for diarrhoea associated intestinal diseases

A study by researchers in the Royal College of Surgeons in Ireland (RCSI) has uncovered a potential new target for the treatment of a range of intestinal diseases that are associated with diarrhoea. Current medications are often ineffective and can have serious side effects so this discovery gives hope for the development of new treatments for sufferers of intestinal disease.

30 Nov 2010

Sanofi Pasteur commences phase II clinical study of vaccine for Clostridium difficile infection prevention

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has started its phase II clinical study of a vaccine for primary prevention of Clostridium difficile infection (CDI). The trial starting in the United States is focused on evaluating prevention of the first episode of CDI in at-risk individuals, which includes adults with imminent hospitalization or current or impending residence in a long-term care or rehabilitation facility.

30 Nov 2010

Drugs that target DNA in later-stage cancers could be effective in treating breast tumors

Breast cancers that arise sporadically, rather than through inheritance of certain genes, likely start with defects of DNA repair mechanisms that allow environmentally triggered mutations to accumulate, according to researchers at the University of Pittsburgh School of Medicine, Magee-Womens Hospital of UPMC and the University of Pittsburgh Cancer Institute.

30 Nov 2010

Drugs News and Research

Underwood-Memorial Hospital joins Jefferson Neuroscience Network as New Jersey participant

Research shows anti-microbial medications lead to acute liver failure

GenSpera expands G-202 Phase I safety trial to CTRC at University of Texas Health Science Center

PhaseBio initiates Glymera Phase 1/2a clinical trial in patients with Type 2 diabetes

NIA awards Aphios Phase I Fast Track SBIR grant for development of novel AD nanodrug

New findings offer insights into novel treatment avenue for Crohn's Disease, sarcoidosis

Ikaria initiates enrollment in LUCASSIN Phase III trial for HRS Type 1

Opinions: Obama's Global Fund pledge; harm reduction in Iran; HIV prevention; African development

Intellikine and MMRC commence INK128 Phase I trial in multiple myeloma

First Edition: November 30, 2010

Prescription rates for controlled medications double for teens, young adults

First-ever selective irreversible inhibition of viral protease using targeted covalent drug

Emergency artesunate suppositories are cost-effective intervention for children with suspected severe malaria

State legislatures ask: Are insurers practicing medicine without a license?

FG-2216 drug offers new treatment option for kidney disease-related anemia

Resverlogix files new patent for dosing combinations of RVX-208, statin therapeutics

International Harm Reduction Conference to focus on HIV/AIDS epidemic

RCSI researchers discover potential new target for diarrhoea associated intestinal diseases

Sanofi Pasteur commences phase II clinical study of vaccine for Clostridium difficile infection prevention

Drugs that target DNA in later-stage cancers could be effective in treating breast tumors

Drug Discovery - Second Edition eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News